title: Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers.
abstract: Six patients with persistent corneal epithelial defects that failed to improve with standard therapy were treated with topical fibronectin in a phase I uncontrolled trial. Fibronectin was purified from autologous plasma by affinity chromatography and administered topically, 0.5 mg/ml five times a day, for three weeks. Complete reepithelialization was achieved in five patients: three healed three to 17 days after initiation of treatment while two healed one to two weeks after discontinuation of topical fibronectin. No side effects were observed. Over a follow-up period of three to 18 months, two recurrences were noted.
authors: Hilles Immunology Laboratory, Massachusetts Eye and Ear Infirmary, Boston.
authors: T M
authors: TM
authors: Phan
authors: C S
authors: CS
authors: Foster
authors: S A
authors: SA
authors: Boruchoff
authors: L M
authors: LM
authors: Zagachin
authors: R B
authors: RB
authors: Colvin
mesh_terms: D000287:Administration, Topical; D000368:Aged; D003315:Cornea / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D003320:Corneal Ulcer / Q000188:drug therapy / Q000473:pathology; D004341:Drug Evaluation; D004848:Epithelium / Q000473:pathology; D005260:Female; D005353:Fibronectins / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014792:Visual Acuity; D014945:Wound Healing
chemical_list: D005353:Fibronectins